MOGAD Diagnosis
MOGAD diagnosis requires detection of serum MOG-IgG antibodies using cell-based assays in patients with compatible clinical-radiological phenotypes, with the 2023 International MOGAD Panel criteria providing the definitive diagnostic framework 1.
Core Diagnostic Criteria
The diagnosis of MOGAD fundamentally rests on three pillars 1:
- Positive serum MOG-IgG detected by cell-based assay (the gold standard methodology)
- Compatible core clinical phenotype (see below)
- Exclusion of alternative diagnoses (particularly MS and AQP4-positive NMOSD)
Clinical Phenotypes That Warrant MOG-IgG Testing
Test for MOG-IgG when patients present with 2:
- Optic neuritis - especially bilateral, recurrent, or with longitudinally extensive optic nerve lesions (>50% of distance from nerve head to chiasm) with perioptic enhancement
- Longitudinally extensive transverse myelitis (LETM) - spanning ≥3 vertebral segments
- Acute disseminated encephalomyelitis (ADEM) - particularly in children
- Brainstem/cerebellar encephalitis
- Cerebral cortical encephalitis with seizures
- Area postrema syndrome (intractable hiccups/nausea/vomiting)
MRI Features Supporting MOGAD
Brain imaging characteristics that increase pre-test probability 2, 3:
- Absence of MS-typical features: No Dawson's fingers, no ovoid periventricular lesions, no U-fiber lesions
- Fluffy, poorly demarcated lesions rather than sharp MS-like lesions
- Deep gray matter involvement (thalamus, basal ganglia)
- Brainstem lesions - often large and edematous
Spinal cord features 2:
- Longitudinally extensive lesions (≥3 segments)
- Central gray matter predominance
- Conus involvement
Optic nerve features 2:
- Longitudinally extensive involvement
- Bilateral involvement
- Perioptic enhancement (optic nerve sheath involvement)
Laboratory Testing Methodology
Critical Testing Requirements 2
Use only cell-based assays with full-length human MOG protein - ELISA methods using denatured peptides are obsolete and unreliable.
Test serum, not CSF - MOG-IgG is produced extrathecally; CSF-only positivity should prompt retesting and consideration of false-positive result 2.
Timing matters critically 4:
- Test during acute attack when titers are highest
- Approximately 25% of patients become low-positive by 6 months post-onset
- If initially negative but suspicion remains high, retest during acute relapse or within 1-3 months after plasma exchange
Interpreting Antibody Results
Clear-positive titers (typically >1:160, assay-dependent): Sufficient for diagnosis with compatible phenotype 1.
Low-positive titers 1, 5: Require additional supportive clinical or MRI features:
- Bilateral optic neuritis
- LETM
- ADEM-like presentation
- Absence of MS-typical MRI features
- CSF neutrophilic pleocytosis (>50 cells/μL or >10% neutrophils)
- Absence of oligoclonal bands
CSF Analysis Supporting MOGAD 2
- Neutrophilic pleocytosis - present in 64% with pleocytosis (median 22% neutrophils; can exceed 50 cells/μL)
- Absence of oligoclonal bands - found in only 12-13% of MOGAD patients versus 98% in MS
- Absence of MRZ reaction (measles/rubella/zoster intrathecal antibody synthesis) - typical of MS, not MOGAD
Red Flags That Challenge a Positive MOG-IgG Result 2
Immediately question the diagnosis if you see 2:
- Progressive disease course without relapses (SPMS, PPMS patterns)
- MS-typical MRI: Dawson's fingers, ovoid periventricular lesions, inferior temporal lobe lesions
- Positive MRZ reaction in CSF
- Borderline/low titers at or just above cutoff with atypical clinical picture
- Double-positive MOG-IgG and AQP4-IgG (extremely rare; retest both)
- CSF-only positivity with negative serum
- Combined central and peripheral demyelination (MOG not expressed peripherally)
In these scenarios, retest using a different cell-based assay methodology and consider seeking expert consultation 2.
Diagnostic Algorithm
Step 1: Identify compatible clinical phenotype (optic neuritis, myelitis, ADEM, brainstem/cerebellar syndrome, cortical encephalitis)
Step 2: Obtain MRI brain, orbits, and/or spine depending on presentation
- Look for MOGAD-supportive features
- Actively exclude MS-typical patterns
Step 3: Send serum MOG-IgG via cell-based assay
- Optimal timing: During acute attack or within 6 months of onset
- If negative but high suspicion: Retest during next attack
Step 4: Perform lumbar puncture
- Check cell count with differential (look for neutrophils)
- Oligoclonal bands
- Consider MRZ reaction if available
Step 5: Test for AQP4-IgG to exclude NMOSD
Step 6: Apply 2023 MOGAD criteria 1:
- If clear-positive MOG-IgG + compatible phenotype + no better alternative = MOGAD diagnosis
- If low-positive MOG-IgG: Ensure ≥1 supportive feature present (bilateral ON, LETM, ADEM, neutrophilic CSF, absence of MS features)
- If red flags present: Retest and reconsider diagnosis
Critical Pitfalls to Avoid
Do not screen unselected MS populations 2 - This dramatically reduces positive predictive value. Even with 99% specific assays, false-positives will outnumber true-positives when prevalence is low.
Do not use ELISA or non-cell-based assays 2 - These detect antibodies to denatured MOG and lack clinical validity.
Do not dismiss low-positive results without proper evaluation 4, 5 - These may represent true MOGAD with delayed testing or partial treatment effect. Ensure supportive features are thoroughly assessed.
Do not test CSF instead of serum 2 - This inverts the expected pattern and suggests false-positive result.
Do not diagnose MOGAD with MS-typical imaging 2 - Dawson's fingers, U-fiber lesions, and ovoid periventricular lesions are incompatible with MOGAD.
The 2023 International MOGAD Panel criteria demonstrate 97-98% sensitivity and 99-100% specificity in validation studies 4, 6, making them the current diagnostic standard. However, their performance depends critically on proper patient selection, optimal testing timing, and rigorous application of supportive features for low-positive results.